Yazar "Bozkuş, Fulsen" için listeleme
-
Are elderly and aged asthma different diseases? Results of a multicenter study
Çelebioğlu, Ebru; Aktaş, Özge Öztürk; Gemicioğlu, Bilun; Yılmaz, Nafiye; Bozkuş, Fulsen; Ayhan, Vehbi; Kalpaklıoğlu, Füsun; Erkekol, Ferda Öner; Havlucu, Yavuz; Erel, Fuat (European Respiratory Soc Journals Ltd, 2018)Aim: The aim of the present study was to evaluate asthma in the elderly population, and compare disease characteristics between patients diagnosed <60 (aged asthma, early onset asthma) and ≥ 60 (elderly asthma) years of ... -
Carotid intima-media thickness in chronic obstructive pulmonary disease and survival: A multicenter prospective study
Gülbaş, Gazi; Turan, Onur; Sarıoğlu, Nurhan; Diken, Özlem Ercen; Ogan, Nalan; Kadıoğlu, Esra Ekbiç; Kurtipek, Ercan; Bozkuş, Fulsen (Wiley, 2019)Introduction Chronic obstructive pulmonary disease (COPD) is associated with increased cardiovascular morbidity and mortality. Carotid intima-media thickness (CIMT) is a noninvasive method assessing atherosclerosis. Objective ... -
Disease history of patients with COPD
Suerdem, Mecit; Sarıoğlu, Nurhan; Ogan, Nalan; Arslan, Sertaç; Yıldırım, Gülfem; Diken, Özlem Ercen; Bozkuş, Fulsen; Gülbaş, Gazi; Demirci, Nilgün Yılmaz (Kare Publ, 2022)BACKGROUND AND AIM: This study aimed to obtain real-life data of patients diagnosed with chronic obstructive pulmonary disease (COPD) at least one year ago, including smoking history, inhaler device training, and the ... -
Long acting B-2 agonists (LABA) or anticholinergics (LAMA): Which one is more efficient in Group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoğlu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (European Respiratory Soc Journals Ltd, 2021)Introduction: Long-acting anticholinergic (LAMA) or beta-2 agonists (LABA) for symptom control in symptomatic group A COPD patients in GOLD guideline, however, there is no mention of priority or superiority between the two ... -
Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): Which one may be the first option in group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoglu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (Springer Heidelberg, 2024)IntroductionLong-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there ...
